Nonculprit Artery Myocardial Infarction and Complex Coronary Lesions in Anterior ST-Elevated Myocardial Infarction Patients: Data from the CIRCUS Study.

Acute myocardial infarction Cardiovascular image processing Coronary multivessel disease Distal embolization Magnetic resonance imaging

Journal

Cardiology
ISSN: 1421-9751
Titre abrégé: Cardiology
Pays: Switzerland
ID NLM: 1266406

Informations de publication

Date de publication:
Historique:
received: 12 06 2020
accepted: 02 06 2021
pubmed: 5 8 2021
medline: 22 12 2021
entrez: 4 8 2021
Statut: ppublish

Résumé

Periprocedural myocardial infarctions have been reported in the setting of planned percutaneous coronary intervention (PCI). We assessed the prevalence of nonculprit artery acute myocardial infarction (NCAMI) and its relationship with coronary artery characteristics, final infarct size, and 1-year adverse clinical outcomes in a population of anterior ST-elevated myocardial infarction (STEMI) patients. Late gadolinium-enhanced cardiac magnetic resonance (LGE-CMR) studies were performed within 7 days of admission in 129 anterior STEMI patients from the CIRCUS trial treated by primary PCI. Infarct in the noninfarct artery territory (circumflex, right coronary) was assessed on LGE-CMR and T2-weighted images. Eleven (8.5%) patients exhibited NCAMI. The only independent characteristic significantly associated with NCAMI was the presence of multiple complex coronary lesions (odds ratio = 12.9, 95% confidence interval [3.1-53.4]; p < 0.001). There was a significantly increased infarct size in NCAMI patients compared to patients without NCAMI (45.8 ± 20.4% of the left ventricle [LV] vs. 31.0 ± 15.1% of LV, respectively; p = 0.02), with lower LV ejection fraction (46 ± 10% vs. 34 ± 8%, respectively; p < 0.001). NCAMIs are present in 8.5% of anterior STEMI patients and are significantly associated with multiple complex coronary lesions without significant relationship to any revascularization procedural technique. NCAMI was associated with a greater infarct size and reduced LVEF but not worse clinical outcomes at 1 year.

Identifiants

pubmed: 34348264
pii: 000518137
doi: 10.1159/000518137
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

728-736

Informations de copyright

© 2021 S. Karger AG, Basel.

Auteurs

Mathieu Schaaf (M)

CHU de Lyon, Hôpital Cardiovasculaire Louis Pradel, Centre d'Investigation Clinique, INSERM 1407, Hospices Civils de Lyon, Lyon, France.

Pierre Croisille (P)

Radiology Department, Hôpital Nord, CHU Saint-Etienne, Saint Etienne, France.

Agathe Py (A)

CHU de Lyon, Hôpital Cardiovasculaire Louis Pradel, Fédération de Cardiologie, Hospices Civils de Lyon, Lyon, France.

François Roubille (F)

Cardiology Department, Hôpital Arnaud de Villeuneuve, CHU de Montpellier, Montpellier, France.

Loic Biere (L)

Cardiology Department, CHU d'Angers, Angers, France.

Thomas Bochaton (T)

CHU de Lyon, Hôpital Cardiovasculaire Louis Pradel, Centre d'Investigation Clinique, INSERM 1407, Hospices Civils de Lyon, Lyon, France.

Thibault Perret (T)

Cardiology Department, Centre Hospitalier, St Joseph Saint Luc, Lyon, France.

Loic Belle (L)

Cardiology Department, Centre Hospitalier d'Annecy, Annecy, France.

Fabien De Poli (F)

Cardiology Department, CHU d'Haguenau, Haguenau, France.

Thomas Hovasse (T)

Cardiology Department, Jacques Cartier Institute, Massy, France.

Olivier Lairez (O)

Cardiology Department, Hôpital Rangueil, CHU de Toulouse, Toulouse, France.

Inesse Boussaha (I)

CHU de Lyon, Hôpital Cardiovasculaire Louis Pradel, Centre d'Investigation Clinique, INSERM 1407, Hospices Civils de Lyon, Lyon, France.

Gilles Rioufol (G)

CHU de Lyon, Hôpital Cardiovasculaire Louis Pradel, Centre d'Investigation Clinique, INSERM 1407, Hospices Civils de Lyon, Lyon, France.

Fabrice Prunier (F)

Cardiology Department, CHU d'Angers, Angers, France.

Michel Ovize (M)

CHU de Lyon, Hôpital Cardiovasculaire Louis Pradel, Centre d'Investigation Clinique, INSERM 1407, Hospices Civils de Lyon, Lyon, France.

Nathan Mewton (N)

CHU de Lyon, Hôpital Cardiovasculaire Louis Pradel, Centre d'Investigation Clinique, INSERM 1407, Hospices Civils de Lyon, Lyon, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH